1/3/2023 7:06:14 AM
RedHill Publishes Positive Phase 2 Study Results With Once-Daily Oral RHB-107 In Non-Hospitalized COVID-19
12/2/2022 9:05:43 AM
RedHill Biopharma Prices $8.0 Mln Underwritten Public Offering
11/29/2022 8:05:05 AM
RedHill Biopharma Q3 Net Revenues $17.55 Mln Vs. $21.61 Mln Last Year
11/14/2022 6:17:24 AM
RedHill Biopharma Agrees In Principle With HCR To Extinguish All Debt Obligations In Exchange For Movantik
11/7/2022 9:55:20 AM
RedHill Biopharma Q2 Loss/shr Narrows To $0.02 From $0.06 Prior Year
10/19/2022 7:12:09 AM
RedHill Biopharma's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
10/18/2022 7:08:54 AM
RedHill Biopharma Announces Receipt Of Nasdaq Notification Regarding Minimum Bid Price Deficiency
10/3/2022 7:43:34 AM
RedHill's Oral Antivirals, Opaganib And RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
8/17/2022 8:02:14 AM
RedHill Biopharma Announces EU Orphan Drug Designation For RHB-204 For Nontuberculous Mycobacteria Infections
6/23/2022 7:10:16 AM
RedHill Biopharma Q1 Net Revenues $18.2 Mln Vs $22.1 Mln Last Year
5/9/2022 8:37:34 AM
RedHill Biopharma Announces $15 Mln Registered Direct Offering With Leading Healthcare Investor
3/17/2022 8:12:08 AM
RedHill Biopharma Q4 Net Revenues $22.1 Mln Vs $21.6 Mln In Q3
12/6/2021 7:06:13 AM
RedHill Biopharma: Opaganib Mechanism Not Impacted By Viral Spike-Protein Mutations, Including Omicron Mutations
11/30/2021 7:15:19 AM
RedHill Biopharma Q3 Loss/shr $0.05 Same With Last Year